800
Participants
Start Date
December 20, 2024
Primary Completion Date
August 15, 2025
Study Completion Date
August 31, 2025
Rapid point of care test to detect host immune response in ARI
FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, in vitro detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), directly from fingerstick blood to aid in the differentiation of bacterial from non-bacterial acute respiratory infections.
Hillcrest Medical Research, LLC, Orange City
Trujillo Medical Center, Miramar
L&C, Miami
Hometown Urgent Care and Research, Beavercreek
HMG Clinical Research/Herrera Medical Group, Bedford
Ascada Health, Katy
Exer Urgent Care, Pasadena
Ascada Health, Fullerton
Lead Sponsor
Biomedical Advanced Research and Development Authority
FED
Lumos Diagnostics
INDUSTRY